These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 16934458)

  • 1. Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors.
    El Abdellaoui H; Varaprasad CV; Barawkar D; Chakravarty S; Maderna A; Tam R; Chen H; Allan M; Wu JZ; Appleby T; Yan S; Zhang W; Lang S; Yao N; Hamatake R; Hong Z
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5561-6. PubMed ID: 16934458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors.
    Han S; Zhou V; Pan S; Liu Y; Hornsby M; McMullan D; Klock HE; Haugen J; Lesley SA; Gray N; Caldwell J; Gu XJ
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5467-73. PubMed ID: 16199156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions.
    Heald RA; Jackson P; Savy P; Jones M; Gancia E; Burton B; Newman R; Boggs J; Chan E; Chan J; Choo E; Merchant M; Rudewicz P; Ultsch M; Wiesmann C; Yue Q; Belvin M; Price S
    J Med Chem; 2012 May; 55(10):4594-604. PubMed ID: 22506516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.
    Wallace EM; Lyssikatos J; Blake JF; Seo J; Yang HW; Yeh TC; Perrier M; Jarski H; Marsh V; Poch G; Livingston MG; Otten J; Hingorani G; Woessner R; Lee P; Winkler J; Koch K
    J Med Chem; 2006 Jan; 49(2):441-4. PubMed ID: 16420026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel, selective and potent Chk2 inhibitors.
    Larson G; Yan S; Chen H; Rong F; Hong Z; Wu JZ
    Bioorg Med Chem Lett; 2007 Jan; 17(1):172-5. PubMed ID: 17035018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
    Spicer JA; Rewcastle GW; Kaufman MD; Black SL; Plummer MS; Denny WA; Quin J; Shahripour AB; Barrett SD; Whitehead CE; Milbank JB; Ohren JF; Gowan RC; Omer C; Camp HS; Esmaeil N; Moore K; Sebolt-Leopold JS; Pryzbranowski S; Merriman RL; Ortwine DF; Warmus JS; Flamme CM; Pavlovsky AG; Tecle H
    J Med Chem; 2007 Oct; 50(21):5090-102. PubMed ID: 17880056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK1/2 is a critical regulator of microtubule assembly and spindle organization during rat oocyte meiotic maturation.
    Sun SC; Xiong B; Lu SS; Sun QY
    Mol Reprod Dev; 2008 Oct; 75(10):1542-8. PubMed ID: 18270979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
    Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors.
    Varaprasad CV; Barawkar D; El Abdellaoui H; Chakravarty S; Allan M; Chen H; Zhang W; Wu JZ; Tam R; Hamatake R; Lang S; Hong Z
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3975-80. PubMed ID: 16725322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
    Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
    Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme kinetics and binding studies on inhibitors of MEK protein kinase.
    VanScyoc WS; Holdgate GA; Sullivan JE; Ward WH
    Biochemistry; 2008 Apr; 47(17):5017-27. PubMed ID: 18393446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of biologically active N-methyl derivatives of amidines and cyclized five-membered products of amidines with oxalyl chloride.
    Sondhi SM; Dinodia M; Jain S; Kumar A
    Eur J Med Chem; 2008 Dec; 43(12):2824-30. PubMed ID: 18022734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synthesis of three 4-substituted benzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase.
    Bridges AJ; Lee A; Schwartz CE; Towle MJ; Littlefield BA
    Bioorg Med Chem; 1993 Dec; 1(6):403-10. PubMed ID: 8087561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.
    Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):373-382. PubMed ID: 29488172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
    West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.
    Iino T; Tsukahara D; Kamata K; Sasaki K; Ohyama S; Hosaka H; Hasegawa T; Chiba M; Nagata Y; Eiki J; Nishimura T
    Bioorg Med Chem; 2009 Apr; 17(7):2733-43. PubMed ID: 19282189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy.
    Uchida M; Okazaki K; Mukaiyama H; Isawa H; Kobayashi H; Shiohara H; Muranaka H; Kai Y; Kikuchi N; Takeuchi H; Yokoyama K; Tsuji E; Ozawa T; Hoyano Y; Koizumi T; Misawa K; Hara K; Nakano S; Murakami Y; Okuno H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4682-7. PubMed ID: 18667303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.
    Berger DM; Dutia M; Powell D; Floyd MB; Torres N; Mallon R; Wojciechowicz D; Kim S; Feldberg L; Collins K; Chaudhary I
    Bioorg Med Chem; 2008 Oct; 16(20):9202-11. PubMed ID: 18815050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.
    Riggs JR; Kolesnikov A; Hendrix J; Young WB; Shrader WD; Vijaykumar D; Stephens R; Liu L; Pan L; Mordenti J; Green MJ; Sukbuntherng J
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2224-8. PubMed ID: 16458507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.